Minelu Sonnenschein - Medigus VP of Operations

MDGS Stock  USD 2.84  0.16  5.97%   

VP

Dr. Minelu Menashe Sonnenschein was appointed Vice President Operations Israel at Medigus Ltd. effective June 1, 2014. Prior to this role, He served as Vice President Research Development at the Company from January 1, 2000 since 2014.
Age 50
Tenure 10 years
Professional MarksPh.D
Address 10 Hanechoshet, Tel Aviv, Israel, 6971072
Phone972 73 370 4691
Webhttps://www.medigus.com
Sonnenschein holds a BSc degree and a Doctorate of Science degree in Electrical and Electronics Engineering, both from Ben Gurion University.

Medigus Management Efficiency

The company has return on total asset (ROA) of (0.0663) % which means that it has lost $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3072) %, meaning that it created substantial loss on money invested by shareholders. Medigus' management efficiency ratios could be used to measure how well Medigus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.22 in 2024. Return On Assets is likely to drop to -0.1 in 2024. At this time, Medigus' Asset Turnover is comparatively stable compared to the past year.
The company currently holds 10.13 M in liabilities with Debt to Equity (D/E) ratio of 0.27, which may suggest the company is not taking enough advantage from borrowing. Medigus Ltd ADR has a current ratio of 1.35, which is within standard range for the sector. Debt can assist Medigus until it has trouble settling it off, either with new capital or with free cash flow. So, Medigus' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medigus Ltd ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medigus to invest in growth at high rates of return. When we think about Medigus' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

VP Age

Kari StevensCigna Corp
N/A
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel. Medigus operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Medigus Ltd ADR (MDGS) is traded on NASDAQ Exchange in USA. It is located in 10 Hanechoshet, Tel Aviv, Israel, 6971072 and employs 77 people. Medigus is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Medigus Ltd ADR Leadership Team

Elected by the shareholders, the Medigus' board of directors comprises two types of representatives: Medigus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigus. The board's role is to monitor Medigus' management team and ensure that shareholders' interests are well served. Medigus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ilan Oren, Executive Officer
Efrat Venkert, External Director
Anat Naschitz, Director
Yaron Silberman, Chief Ltd
Ori Hershkovitz, External Director
Yair Rabinovitch, Director
Menashe Sonnenschein, Vice President - Operations
Gilad Mamlok, CFO
Christopher Rowland, CEO and Director
Eitan Machover, Independent Director
Minelu Sonnenschein, VP of Operations
Oded Yatzkan, Director of Fin. and Accounting and VP
Nissim Darvish, Chairman of the Board
Jeremy Starkweather, Director of Sales, Director of Marketing-United States
Yuval Yanai, Director
Aviel Shapira, Medical Director
Yair Rabinowitch, Director
Liron Carmel, Chief Officer
Erez Haimovitz, Director
Tali Dinar, Chief Officer
Doron Birger, Director
Tatyana Yossef, Controller
Yaron Zilberman, Vice President - Sales and Marketing

Medigus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medigus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Medigus Ltd ADR is a strong investment it is important to analyze Medigus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Medigus' future performance. For an informed investment choice regarding Medigus Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medigus Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Medigus Ltd ADR information on this page should be used as a complementary analysis to other Medigus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Medigus Stock analysis

When running Medigus' price analysis, check to measure Medigus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigus is operating at the current time. Most of Medigus' value examination focuses on studying past and present price action to predict the probability of Medigus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigus' price. Additionally, you may evaluate how the addition of Medigus to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Transaction History
View history of all your transactions and understand their impact on performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Is Medigus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medigus. If investors know Medigus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medigus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.70)
Revenue Per Share
67.313
Quarterly Revenue Growth
0.527
Return On Assets
(0.07)
Return On Equity
(0.31)
The market value of Medigus Ltd ADR is measured differently than its book value, which is the value of Medigus that is recorded on the company's balance sheet. Investors also form their own opinion of Medigus' value that differs from its market value or its book value, called intrinsic value, which is Medigus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medigus' market value can be influenced by many factors that don't directly affect Medigus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medigus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medigus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medigus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.